Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kymera Therapeutics (KYMR) Cash from Operations (2019 - 2025)

Kymera Therapeutics (KYMR) has disclosed Cash from Operations for 7 consecutive years, with 66747000.0 as the latest value for Q4 2025.

  • Quarterly Cash from Operations fell 8.03% to 66747000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 232891000.0 through Dec 2025, down 19.74% year-over-year, with the annual reading at 232891000.0 for FY2025, 19.74% down from the prior year.
  • Cash from Operations for Q4 2025 was 66747000.0 at Kymera Therapeutics, down from 27110000.0 in the prior quarter.
  • The five-year high for Cash from Operations was 8045000.0 in Q4 2023, with the low at 79150000.0 in Q1 2025.
  • Average Cash from Operations over 5 years is 40612450.0, with a median of 39260500.0 recorded in 2022.
  • The sharpest move saw Cash from Operations surged 120.35% in 2023, then plummeted 867.98% in 2024.
  • Over 5 years, Cash from Operations stood at 38352000.0 in 2021, then dropped by 3.09% to 39536000.0 in 2022, then soared by 120.35% to 8045000.0 in 2023, then tumbled by 867.98% to 61784000.0 in 2024, then decreased by 8.03% to 66747000.0 in 2025.
  • According to Business Quant data, Cash from Operations over the past three periods came in at 66747000.0, 27110000.0, and 59884000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.